Trials / Completed
CompletedNCT03328364
A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 211 (actual)
- Sponsor
- Astellas Pharma a/s · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to provide real world data on treatment with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients. The primary purpose is to evaluate overall survival (OS) in mCRPC patients treated with enzalutamide who have previously undergone treatment with chemotherapy (docetaxel) (post chemo patients). This study will also evaluate treatment duration with enzalutamide in patients pre- and post-chemo.
Detailed description
The data source in this study is a local hospital registry created from a patient follow up of prostate cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | enzalutamide | oral |
| DRUG | docetaxel | intravenous infusion |
Timeline
- Start date
- 2017-12-01
- Primary completion
- 2017-12-24
- Completion
- 2017-12-24
- First posted
- 2017-11-01
- Last updated
- 2024-11-21
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT03328364. Inclusion in this directory is not an endorsement.